Literature DB >> 23197445

Compassionate use of the self-expandable medtronic CoreValve prosthesis for the treatment of pure aortic regurgitation in a patient at prohibitive risk for surgical valve replacement.

H A Hildebrandt1, R Erbel, P Kahlert.   

Abstract

Transcatheter aortic valve implantation (TAVI) is a viable treatment option for high- and prohibitive-risk patients with severe, calcified pure or predominant aortic valve stenosis, but not for pure aortic valve regurgitation. In fact, the use of TAVI for this indication is even considered unlikely due to the lack of calcium which appears essential for anchoring the stent-valve and prevents dislocation. We report a case of a patient with severe, symptomatic pure aortic regurgitation, and a history of two previous open-heart surgeries who was successfully treated by compassionate use implantation of an oversized Medtronic CoreValve prosthesis as an ultima ratio treatment option.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Keywords:  aortic valve; regurgitation; valvular heart disease

Mesh:

Year:  2013        PMID: 23197445     DOI: 10.1002/ccd.24763

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  3 in total

1.  Transcatheter Advances in the Treatment of Adult and Congenital Valvular Heart Disease.

Authors:  Jayendrakumar S Patel; Samir R Kapadia; Lourdes Prieto; E Murat Tuzcu; Amar Krishnaswamy
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-11

Review 2.  Transcatheter aortic valve implantation (TAVI) in patients with aortic regurgitation.

Authors:  Matthias Thielmann; Konstantinos Tsagakis; Mohamad El Gabry; Heinz Jakob; Daniel Wendt
Journal:  Ann Cardiothorac Surg       Date:  2017-09

Review 3.  Transcatheter Aortic Valve Implantation for Pure Native Aortic Regurgitation: The Last Frontier.

Authors:  Ana Paula Tagliari; Rodrigo Petersen Saadi; Eduardo Keller Saadi
Journal:  J Clin Med       Date:  2022-09-01       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.